Silva Adriana Torres da, Vieira Érica Leandro Marciano, Silva Ana Cristina Simões E, Petroianu Andy
Universidade Federal de Minas Gerais - Faculty of Medicine - Department of Surgery - Belo Horizonte (MG), Brazil.
Acta Cir Bras. 2025 Aug 8;40:e405425. doi: 10.1590/acb405425. eCollection 2025.
PURPOSE: To evaluate peripheral blood mononuclear cells (PBMCs) from patients with advanced head and neck squamous cell carcinoma (HNSCC) in comparison with healthy volunteers, as they can be potential biomarkers. METHODS: Immunophenotyping was performed using flow cytometry of blood mononuclear cells from two groups of adult men: group 1 (n = 14), diagnosed with HNSCC (mouth, larynx, and hypopharynx); and group 2 (n = 14), volunteers, healthy, and without the use of drugs. The cell groups studied were T lymphocytes (CD3, CD4, CD8, CD56 and CD69), B lymphocytes (CD19, CD69), neutrophils (CD11a, CD16, CD66b, HLA-DR), and monocytes (CD14, CD86). RESULTS: In group 1, there were an increase in CD3+CD4+ T lymphocytes (p < 0.001) and NK 56+ cells (p = 0.009) and a decrease in CD3+CD8+ T lymphocytes (p = 0.02) in comparison with group 2. In patients with HNSCC, an increase was found in the expression of the CD69 marker in CD3+CD4+ T lymphocytes (p = 0.03) and CD19+ B lymphocytes (p = 0.01) when compared to healthy volunteers. CONCLUSION: HNSCC triggers a systemic inflammatory response with a decrease in CD8 T cells and an increase in CD4 T and CD56 natural killer cells. CD69 early activation marker was expressed by T and B cells.
目的:评估晚期头颈部鳞状细胞癌(HNSCC)患者的外周血单个核细胞(PBMC),并与健康志愿者进行比较,因为它们可能是潜在的生物标志物。 方法:对两组成年男性的血液单个核细胞进行流式细胞术免疫表型分析:第1组(n = 14),诊断为HNSCC(口腔、喉和下咽);第2组(n = 14),志愿者,健康且未使用药物。研究的细胞组包括T淋巴细胞(CD3、CD4、CD8、CD56和CD69)、B淋巴细胞(CD19、CD69)、中性粒细胞(CD11a、CD16、CD66b、HLA - DR)和单核细胞(CD14、CD86)。 结果:与第2组相比,第1组中CD3 + CD4 + T淋巴细胞增加(p < 0.001),NK 56 +细胞增加(p = 0.009),CD3 + CD8 + T淋巴细胞减少(p = 0.02)。与健康志愿者相比,HNSCC患者的CD3 + CD4 + T淋巴细胞(p = 0.03)和CD19 + B淋巴细胞(p = 0.01)中CD69标志物的表达增加。 结论:HNSCC引发全身炎症反应,导致CD8 T细胞减少,CD4 T细胞和CD56自然杀伤细胞增加。T细胞和B细胞表达CD69早期激活标志物。
Biomedicines. 2024-4-5
Immunotargets Ther. 2024-1-9
Cancer Immunol Res. 2023-8-3